SIC
AVDL

Salem Investment Counselors’s Avadel Pharmaceuticals AVDL Stock Holding History

Salem Investment Counselors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-450
Closed -$6.87K – 445
2025
Q3 		$6.87K Hold
450
– – ﹤0.01% 935
2025
Q2 		$3.98K Hold
450
– – ﹤0.01% 973
2025
Q1 		$3.52K Hold
450
– – ﹤0.01% 972
2024
Q4 		$4.73K Hold
450
– – ﹤0.01% 928
2024
Q3 		$5.9K Hold
450
– – ﹤0.01% 910
2024
Q2 		$6.33K Hold
450
– – ﹤0.01% 889
2024
Q1 		$7.6K Hold
450
– – ﹤0.01% 871
2023
Q4 		$6.35K Hold
450
– – ﹤0.01% 874
2023
Q3 		$4.63K Hold
450
– – ﹤0.01% 902
2023
Q2 		$7.42K Buy
+450
New +$5.85K ﹤0.01% 869

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salem Investment Counselors's AVDL Position: Q4 2025 in Review

Salem Investment Counselors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 450 shares — an estimated $6.87K sold.

Salem Investment Counselors first reported a position in AVDL in Q2 2023 and held it in 10 quarters. The position peaked at $7.6K in Q1 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Salem Investment Counselors reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 450 Avadel Pharmaceuticals shares in Q4 2025, an estimated $6.87K.
  • Salem Investment Counselors first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Salem Investment Counselors's Avadel Pharmaceuticals position peaked at $7.6K in Q1 2024.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Salem Investment Counselors's 13F filing for Q4 2025, filed 12 Jan 2026.